Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.

Pallanza, M.; Thoueille, P.; Briki, M.; Alves Saldanha, S.; Cavassini, M.; Marzolini, C.

doi:10.1177/13596535251335080

Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.

Details

Download: 40230016.pdf (579.02 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0

Serval ID

serval:BIB_94CAA7C42022

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.

Journal

Antiviral therapy

Author(s)

Pallanza M., Thoueille P., Briki M., Alves Saldanha S., Cavassini M., Marzolini C.

ISSN

2040-2058 (Electronic)

ISSN-L

1359-6535

Publication state

Published

Issued date

04/2025

Peer-reviewed

Oui

Volume

Number

Pages

13596535251335080

Language

english

Notes

Publication types: Journal Article ; Case Reports
Publication Status: ppublish

Abstract

Dolutegravir 50 mg twice daily (BID) dosing is currently recommended in presence of strong inducers of drug metabolism. However, this dosing has been challenged by studies showing similar rates of viral suppression with dolutegravir once daily (QD) compared to BID dosing in presence of the strong inducer rifampicin. We report the case of a 41-year-old man with sustained virological suppression and documented therapeutic dolutegravir concentration on once daily dosing while treated with the strong inducer carbamazepine. Therapeutic drug monitoring can guide the need for twice daily dosing dolutegravir in presence of strong inducers.

Keywords

Humans, Pyridones, Oxazines, Piperazines, Heterocyclic Compounds, 3-Ring/administration & dosage, Heterocyclic Compounds, 3-Ring/therapeutic use, Male, Adult, HIV Infections/drug therapy, HIV Infections/virology, Carbamazepine/therapeutic use, Carbamazepine/administration & dosage, HIV Integrase Inhibitors/administration & dosage, HIV Integrase Inhibitors/therapeutic use, Drug Interactions, Sustained Virologic Response, Drug Monitoring, HIV-1/drug effects, Viral Load/drug effects, HIV, carbamazepine, dolutegravir, once daily, plasma levels, strong inducer

URN

urn:nbn:ch:serval-BIB_94CAA7C420227

OAI-PMH

oai:serval.unil.ch:BIB_94CAA7C42022

DOI

10.1177/13596535251335080

Pubmed

40230016

Web of science

001467170000001

Open Access

Yes